"Scleroderma, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
MeSH Number(s)
C17.300.799.602
C17.800.784.602
Concept/Terms
Scleroderma, Diffuse- Scleroderma, Diffuse
- Scleroderma, Progressive
- Progressive Scleroderma
- Diffuse Cutaneous Systemic Sclerosis
- Sudden Onset Scleroderma
- Scleroderma, Sudden Onset
- Sclerodermas, Sudden Onset
- Sudden Onset Sclerodermas
- Diffuse Systemic Sclerosis
- Diffuse Systemic Scleroses
- Scleroses, Diffuse Systemic
- Sclerosis, Diffuse Systemic
- Systemic Scleroses, Diffuse
- Systemic Sclerosis, Diffuse
- Diffuse Scleroderma
- Sclerosis, Progressive Systemic
- Progressive Systemic Sclerosis
- Systemic Sclerosis, Progressive
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Diffuse".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Diffuse".
This graph shows the total number of publications written about "Scleroderma, Diffuse" by people in Harvard Catalyst Profiles by year, and whether "Scleroderma, Diffuse" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2008 | 2 | 0 | 2 |
2014 | 2 | 0 | 2 |
2015 | 2 | 0 | 2 |
2019 | 2 | 0 | 2 |
2021 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
2023 | 2 | 0 | 2 |
Below are the most recent publications written about "Scleroderma, Diffuse" by people in Profiles.
-
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 09; 75(9):1608-1618.
-
Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology (Oxford). 2023 06 01; 62(6):2060-2069.
-
Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. Rheumatology (Oxford). 2022 08 03; 61(8):3132-3148.
-
Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. Arthritis Res Ther. 2021 11 13; 23(1):283.
-
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther. 2021 06 14; 23(1):170.
-
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136.
-
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. 2020 03; 79(3):379-386.
-
Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non-African Americans. Arthritis Care Res (Hoboken). 2019 09; 71(9):1154-1163.
-
Gauzoma in A Scleroderma Patient Following Open Heart Surgery: A Case Report. Curr Rheumatol Rev. 2019; 15(1):79-81.
-
Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):102-108.